{
  "documents": [
    {
      "id": "cluster_4_doc1",
      "content": "Initial consultation report for PT-4557-23CY noted unexplained neurological symptoms and joint inflammation. Patient reported 6-month symptom progression with increased mobility challenges. Provider ordered specialized CSF analysis and autoimmune panels. Next appointment scheduled for February 15th at Clarkston Valley Neurology.",
      "metadata": {
        "format": "medical_record"
      }
    },
    {
      "id": "cluster_4_doc2",
      "content": "Insurance coverage memo regarding PT-4557-23CY's prion disease diagnostics. BlueStar policy 889344-12 requires peer review for PET scans in rare neurodegenerative cases. Pre-auth team flagged need for second opinion given atypical presentation. Patient coordinator contacted at 423-555-0198 for updated clinical notes.",
      "metadata": {
        "format": "insurance_memo"
      }
    },
    {
      "id": "cluster_4_doc3",
      "content": "Treatment authorization report for 778 Elm Road patient: Approved 6 weeks of plasmapheresis for autoimmune encephalopathy. Network exception granted for out-of-system immunology specialist. Coordination required with Clarkston Valley Infusion Center. Denied IVIG due to formulary restrictions for concurrent prion disease diagnosis.",
      "metadata": {
        "format": "provider_report"
      }
    },
    {
      "id": "cluster_4_doc4",
      "content": "Research brief: 2023 Clarkston Valley case study of prion-autoimmune comorbidity (0.017% prevalence). Notable for faster disease progression than single-pathology cases. Insurance records show 82% denial rate for first-line therapies. Ethical review pending for experimental protocol NR-882.",
      "metadata": {
        "format": "research_note"
      }
    },
    {
      "id": "cluster_4_doc5",
      "content": "Policy update AJM-5543: Autoimmune disorder treatment guidelines revised September 2023. Clarkston Valley region now requires failure of 2 traditional DMARDs before biologic approval. Exception process added for patients with concurrent neurodegenerative conditions. Implementation memo circulated to all network providers.",
      "metadata": {
        "format": "policy_document"
      }
    },
    {
      "id": "cluster_4_doc6",
      "content": "Clarkston Valley Times health section: Local insurers saw 37% increase in autoimmune treatment denials following 2023 policy changes. Patient advocates cite delays in care for complex cases. Regional medical society drafting new network adequacy standards. Next community forum scheduled March 22nd at Valley Hospital.",
      "metadata": {
        "format": "news_article"
      }
    }
  ],
  "metadata": {
    "category": "cluster",
    "cluster_id": "cluster_4",
    "cluster_risk": "MEDIUM",
    "content_summary": "Complex case of comorbid prion disease and autoimmune encephalopathy with insurance authorization challenges and policy impact in Clarkston Valley",
    "person": {
      "entities": [
        [
          "PT-4557-23CY",
          "PATIENT_ID"
        ],
        [
          "778 Elm Road",
          "ADDRESS"
        ],
        [
          "423-555-0198",
          "PHONE_NUMBER"
        ],
        [
          "prion disease",
          "MEDICAL_CONDITION"
        ],
        [
          "autoimmune encephalopathy",
          "MEDICAL_CONDITION"
        ],
        [
          "February 15th",
          "EVENT_DATE"
        ],
        [
          "March 22nd",
          "EVENT_DATE"
        ],
        [
          "Clarkston Valley",
          "LOCATION"
        ],
        [
          "0.017% prevalence",
          "UNIQUE_FACT"
        ],
        [
          "NR-882",
          "PROCESS_ID"
        ]
      ]
    },
    "questions": [
      {
        "q": "Which two rare conditions does patient PT-4557-23CY have?",
        "a": "Prion disease and autoimmune encephalopathy",
        "sources": [
          "cluster_4_doc1"
        ],
        "type": "specific"
      },
      {
        "q": "What policy change affected autoimmune disorder coverage in Clarkston Valley starting September 2023?",
        "a": "Requires failure of 2 traditional DMARDs before biologic approval",
        "sources": [
          "cluster_4_doc5"
        ],
        "type": "general"
      },
      {
        "q": "What treatments were noted for PT-4557-23CY's prion disease alongside immunosuppressants?",
        "a": "Plasmapheresis approved, IVIG denied due to formulary restrictions",
        "sources": [
          "cluster_4_doc2",
          "cluster_4_doc3"
        ],
        "type": "specific"
      },
      {
        "q": "How did 2023 insurance policy changes impact autoimmune treatment in Clarkston Valley?",
        "a": "37% increase in denials, delayed care for complex cases",
        "sources": [
          "cluster_4_doc5",
          "cluster_4_doc6"
        ],
        "type": "general"
      }
    ]
  }
}